Aromatase inhibitors vs. tamoxifen in premenopausal women with estrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomized trials

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials – The Lancet Oncology

Commentaries:

Aromatase Inhibitors May Benefit Premenopausal Women With Breast Cancer – HealthDay

Aromatase inhibitors are better than tamoxifen at reducing the risk of breast cancer recurrence in premenopausal as well as postmenopausal women – Cancer Research UK